

19

SUGGESTED REFERENCES

1. Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. *Diabetes Obes Metab*. 2009;11:150-6.
2. ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycaemic control in type 2 diabetes mellitus. *Endocrine Practice* 2007;13:261-9.
3. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59.
4. ADA Clinical Practice Recommendations. ADA standards of medical care in diabetes-2007. *Diabetes Care* 2007;30(Suppl.1):S4-S41.
5. ADA Clinical Practice Recommendations. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2007;30(Suppl.1):S42-S47.
6. ADA Clinical Practice Recommendations. Standards of medical care. *Diabetes Care* 2008;31(Suppl.1):S12-S54.
7. ADA Clinical Practice Recommendations. Standards of medical care. *Diabetes Care* 2009;32(Suppl.1):S13-61.
8. ADA Position Statement. Hyperglycemic crises in diabetes. *Diabetes Care* 2004;27(Suppl.1):S94-S102.
9. ADA Position Statement. Nutrition recommendations and interventions for diabetes. *Diabetes Care* 2008;31(Suppl. 1): S48-S65.
10. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560-72.
11. American College of Physicians. ACP Diabetes Care Guide: A Team Based Practice Manual and Self Assessment Program. ACP, Philadelphia, 2007.
12. American Diabetes Association Consensus Statement. DKA in infants, children and adolescents. *Diabetes Care* 2006;29;1150-9.
13. American Diabetes Association Position Statement. Continuous subcutaneous insulin infusion. *Diabetes Care* 2004;27(Suppl 1):S110.
14. American Diabetes Association Position Statement. Standards of medical care in diabetes-2006. *Diabetes Care* 2006;29(Suppl 1):S4-S42.
15. American Diabetes Association. American Diabetes Association Complete Guide to Diabetes. 2nd Edition. ADA, Alexandria, 1999.
16. American Diabetes Association. Clinical Practice Recommendations 2009. *Diabetes Care* 2009;32(Supplement 1):S1-98.
17. Armstrong DG, Lavery LA (Editors). *Clinical Care of the Diabetic Foot*. ADA Publ, Alexandria, 2005.
18. Bolan G, Broome CV, Facklam RR, et al. Pneumococcal vaccine efficacy in selected populations in the United States. *Ann Intern Med* 1986;104:1-6.
19. Brown A, Mangione C, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. *J Am Geriatr Soc* 2003;51:S265-80.
20. Canadian Diabetes Association. 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Canadian J Diabetes*. 2003;27(Supplement 2).
21. Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Canadian J Diabetes* 2008;32(Suppl. 1):1-215.
22. CDC Diabetes Cost-Effectiveness Study Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. *JAMA* 2002;287:2542-51.
23. Chobanian AV, Bakris GL, Black HR, et al. The National High Blood Pressure Education Program Coordinating Committee. JNC 7: Complete Report. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42:1206-52.
24. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. *Diabetes Care* 2007;30:2399-400.
25. Cryer PE, Axelrod L, Grossman AB, et al. The Endocrine Society's Clinical Practice Guidelines. Evaluation and management of adult hypoglycemic disorders. *J Clin Endocrinol Metab* 2009;94:709-28.
26. Davidson JK (Editor). *Clinical Diabetes Mellitus: A Problem-Oriented Approach*. Third Edition. Thieme, New York, 2000.
27. DeFronzo RA, Ferrannini E, et al (Editors). *International Textbook of Diabetes Mellitus*. Volume 1-2. Third Edition. John Wiley & Sons, Chichester, 2004.

28. DeGroot LJ, Grossman AB, Marshall JC, et al (Editors). *Endocrinology*. Volume 1. Fifth Edition. Saunders-Elsevier, Philadelphia, 2006.
29. Del Prato S, Felton A-M, Munro N, et al. The Global Partnership for Effective Diabetes Management. Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. *Int J Clin Pract* 2005;59:1345-55.
30. Diabetes Control and Complications Trial Research Group. The effects of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-86.
31. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). *Arch Intern Med*. 2009 Jul 27;169:1307-16.
32. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. *N Engl J Med*. 2008 Jun 12;358(24):2630-3.
33. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. *Lancet* 2006;368(9541):1096-105. Erratum in: *Lancet* 2006;368(9549):1770.
34. Droumaguet C, Balkau B, Simon D, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care* 2006;29:1619-25.
35. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129-39.
36. Edelman D, Olsen MK, Dudley TK, et al. Utility of hemoglobin A1c in predicting diabetes risk. *J Gen Intern Med* 2004;19:1175-80.
37. Equal Employment Opportunity Commission, "Questions and Answers About Diabetes in the Workplace and the Americans with Disabilities Act (ADA)" Oct. 29, 2003 (<http://www.eeoc.gov/facts/diabetes.html>). 26 May 2008).
38. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183-97.
39. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003;26:3160-7.
40. Fisher N (Editor). *Heart Disease and Diabetes*. Martin Dunitz, London, 2003.
41. Fonseca VA (Editor). *Clinical Diabetes: Translating Research into Practice*. Saunders-Elsevier Inc, Philadelphia, 2006.
42. Franz MJ, Bantle JP, Beebe CA, Brunzel JP et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 2002;25:148-198.
43. Ganda O, Beaser R, Blair E, et al. Joslin Diabetes Center & Joslin Clinic Clinical guideline for pharmacological management of type 2 diabetes. 2009;1-9.
44. Gill G (Editor). *Unstable and Brittle Diabetes*. Taylor & Francis, London, 2004.
45. Goldstein BJ, Müller-Wieland D (Editors). *Textbook of Type 2 Diabetes*. Martin Dunitz, London, 2003.
46. Hanley AJ, Zinman B, Sheridan P, Yusuf S, et al. Effect of Rosiglitazone and Ramipril on β -cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. *Diabetes Care* 2010;33:608-13.
47. Heymann AD, Shapiro Y, Chodick G, et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. *Diabetes Care* 2004;27:2581-4.
48. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1C in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. *Clin Chem* 2004;50:166-74.
49. Holman R, Paul S, Bethel M, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. *N Engl J Med* 2008;359:1565-76.
50. Holman RR, Haffner SM, McMurray JJ, Bethel MA, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010;362:1463-76 (Erratum in: *N Engl J Med* 2010;362:1748).
51. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. *Lancet*. 2009 Jun 20;373(9681):2125-35.
52. Huang E, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose in older patients with type 2 diabetes: a decision analysis. *Ann Intern Med* 2008;149:11-9.
53. IDSA & IWGDF guidelines for clinicians diagnosing diabetic foot infections. *Clinical Infectious Diseases*. October 1, 2004.
54. International Diabetes Federation. *Diabetes Atlas 3rd Edition*, Brussels, IDF Publ., 2006.
55. International Diabetes Federation. *IDF Clinical Guidelines Taskforce. Global Guideline for Type 2 Diabetes*. IDF Publ., Brussels, 2005.
56. Inzucchi SE, Porte DJr, Sherwin RS, Baron A (Editors). *The Diabetes Manual: A Primary Care Companion to Ellenberg and Rifkin's Sixth Edition*. McGraw-Hill Medical Publishing Division, New York, 2005.
57. Jameson JL, Kasper DL, Fauci AS, et al (Editors). *Harrison's Endocrinology*. Sixteenth Edition, McGraw-Hill, New York, 2006.
58. Kahn RC, Weir GC, King GL, et al (Editors). *Joslin's Diabetes Mellitus*. Fourteenth Edition. Boston, Lippincott Williams & Wilkins, 2005.
59. Katz P, Gilbert J. Diabetes and cardiovascular disease among older adults: an update on the evidence. *Geriatr Aging* 2008;11:509-14.

60. Kaufman F, Halvorson MJ, Lohry J (Editors). Putting Your Patients on the Pump. Fast Fact Series, ADA Publications, Alexandria, 2001.
61. Lachin JM, Genuth S, Nathan DM, et al, and DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. *Diabetes*. 2008;57:995-1001.
62. Leibovitz H (Editor). Management of Type 2 Diabetes and its Related Disorders. Fourth Edition, ADA Publ, Alexandria, 2004.
63. Leyden R, Standl E, Bartnik M, et al. ESC/EASD Guidelines on pre-diabetes, diabetes and cardiovascular diseases: Executive summary. *European Heart Journal* 2007;28:88-136.
64. Little RR, England JD, Wiedemeyer HM, et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. *Diabetologia* 1994;37:252-6.
65. Little RR, Rohlfing CL, Tennill AL, et al. Effects of sample storage conditions on glycated hemoglobin measurement: evaluation of five different high performance liquid chromatography methods. *Diabetes Technol Ther* 2007;9:36-42.
66. Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five year progress report. *Clin Chem* 2001;47:1985-92.
67. Matthaei S, Bierwirth R, Fritsche A, et al. Medikamentöse antihyperglykämische therapie des diabetes mellitus typ 2: Update der evidenzbasierten leitlinie der DDG. 2008. (<http://www.deutsche-diabetesgesellschaft.de>)
68. Moghissi ES, Korytkowski MT, Dinardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. *Diabetes Care* 2009;32:1119-31, and *Endocrine Practice* 2009;15:1-15.
69. Mulcahy K, Lumber T. The Diabetes Ready Reference for Health Professionals. Clear, concise guidelines for effective patient care. Diagnosis, Monitoring, Insulin Therapy, Oral Medications, Nutrition, Exercise, Complications, Surgery & Hospitalization, More. Second Edition, American Diabetes Association Publ, Alexandria, 2004.
70. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2006;29:1963-72.
71. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes -a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009;32:1-11.
72. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2008;31:173-5.
73. Nathan DM, Cleary PA, Backlund JY, et al and Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005;353:2643-53.
74. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: Implications for care. *Diabetes Care* 2007;30:753-9.
75. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008;31:1473-8.
76. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, for the A1C-Derived Average Glucose (ADAG) Study Group. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008;31:1473-8.
77. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. *Diabetologia* 2007;50:2239-44.
78. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes. 2008. (www.nice.org.uk)
79. NICE Clinical Guideline 2008. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes.2008, pp.1-89. (www.nice.org.uk)
80. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360:1283-97.
81. Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. *Diabetes Technology & Therapeutics* 2008;10: 333-49.
82. Patients information: Alcohol misuse. NHS Direct 2005;1-6.
83. Pickup JC, Williams G (Editors). Textbook of Diabetes. Volume 1-2, Third Edition. Blackwell Publishing, Massachusetts, 2003.
84. Poretsky L (Editor). Principles of Diabetes Mellitus. Kluwer Academic Publishers, Boston, 2002.
85. Prasek M, Bozek T, Metelko Z. Continuous subcutaneous insulin infusion (CSII). *Diabetologia Croatica* 2003;32:111-24.
86. Raben A, Vasilaras TH, Moller AC, Astrup A. Sucrase compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 week of supplementation in overweight subjects. *Am J Clin Nutr* 2002;76:721-729.
87. Reece A, Coustan DR, Gabbe SG (Editors). Diabetes in Women: Adolescence, Pregnancy, and Menopause. Third Edition. Lippincott Williams & Wilkins Philadelphia, 2004.

88. Rodbard HW, Blonde L, Braithwaite SS, et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force 2007. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. *Endocrine Practice* 2007;13 (Suppl 1):1-66.
89. Rosenzweig JL, Ferrannini E, Grundy SM, et al. The Endocrine Society's Clinical Practice Guidelines. Primary prevention of cardiovascular disease and type 2 diabetes in patients at risk. *J Clin Endocrinol Metab* 2008;93:3671-89.
90. Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycosylated hemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes. *Diabetologia*. 22 April 2009 [Epub ahead of print].
91. Satman İ (Editör). *Diabetes Mellitus Özel Sayısı. Türkiye Klinikleri Endokrinoloji* 2003;1:157-68.
92. Satman İ, İmamoğlu Ş, Yılmaz C ve TEMD Diabetes Mellitus Çalışma Grubu. *Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu-2008*. 3. Baskı, Muka Matbaa Reklamcılık Yayıncılık Ltd. Şti., İstanbul, Eylül-2008, s.1-144.
93. Sinclair AJ, Finucane P (Editors). *Diabetes in Old Age. Second Edition*. John Wiley & Sons, Chichester, 1995.
94. Skyler J, Bergenstal R, Bonow R, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and the VA diabetes trials. *Diabetes Care* 2009;32:187-92.
95. Steed DL, Atfanger C, Colaizzi T, et al. Guidelines for treatment of diabetic ulcers. *Wound Rep Reg* 2006;16:680-92.
96. Stolar MW, Hoogwerf BJ, Boyle PJ, Gorshov SM, Wales DO. Managing type 2 diabetes: going beyond glycemic control. *J Managed Care Pharmacy* 2008;14(Suppl S-b): S2-19.
97. Technology Appraisal Guidance No. 57, Issue date February 2003, Review date February 2006 ISBN: 1-84257-269-5 N0195 70k 1P Feb 03 (ABA).
98. TEMD Diabetes Mellitus Çalışma Grubu. *Diabetes Mellitus Tanı, İzlem ve Tedavi Kılavuzu. Türkiye Endokrinoloji ve Metabolizma Derneği*, 2006.
99. The AACE/ADA Task Force on Inpatient Diabetes. American Diabetes Association consensus statement on inpatient diabetes and glycemic control: A call to action. *Diabetes Care* 2006;29:1955-62.
100. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. *J Hypertens* 1993;11:309-17.
101. The International Expert Committee. International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32:1327-34.
102. The International Expert Committee. International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32:1327-34.
103. *The Practical Guide on Identification, Evaluation and Treatment of Overweight and Obesity in Adults*. NIH Publications, 2000.
104. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program. *JAMA*, 2001;285:2486-97.
105. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27:155-61. Erratum in: *Diabetes Care* 2004;27:856.
106. Tüzün M, Çetinkalp Ş (Editörler). *Diabetes Mellitus Cep ve El Kılavuzu*. Asya Tıp Kitapevi, İzmir, 2004.
107. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854-65.
108. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53.
109. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006;354:449-61.
110. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001;345:1359-67.
111. Warshaw HS, Bolderman KM (Editors). *Practical Carbohydrate Counting: A How to Teach Guide for Health Professionals*. ADA Publications, Alexandria, 2001.
112. Wass JAM, Shalet SM, Gale E, Amiel S (Editors). *Oxford Textbook of Endocrinology and Diabetes*. Oxford University Press, Oxford, 2002.
113. Weykamp C, John WG, Mosca A, et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. *Clin Chem* 2008;54:240-8.
114. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol*. 2008 Dec;126:1707-15.
115. WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. WHO, Geneva, 1999. WHO/NCD/NCS/99.2.
116. Wolsdorf J, Glaser N, Sperling MA. Diabetic ketoacidosis in infants, children and adolescents: A consensus statement from the American Diabetes Association. *Diabetes Care* 2006;29:1150-9.
117. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. WHO Document Production Services, Geneva, 2006, pp. 1-41.